What do we do?
Simply put, we want to help pancreatic cancer patients, and their doctors, to find and understand accurate and reliable information about that specific patient’s cancer that could help them to decide what the most suitable type of treatment is. Click on the accordions below to find out more about our clinical studies and our research.
The Precision-Panc Master Protocol is a “portal” protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Study) examining different treatment regimens and/or biomarker development.
Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS studies.
Our primary objective is to establish a mechanism and framework to recruit and screen patients with pancreatic cancer to perform molecular profiling, evaluation of circulating biomarkers, and enable enrolment into Precision-Panc PRIMUS studies.The Precision-Panc Master Protocol is only open at Glasgow Royal Infirmary and the Beatson West of Scotland Cancer Centre at this time. Further sites will open later in 2018.
PRIMUS 001 - A PRECISION PANC CLINICAL STUDY
An adaptive phase II study of two different treatment options in patients with metastatic pancreatic cancer, with integrated biomarker evaluation.
PRIMUS 001 is a multicentre, randomised, open label, two arm, phase II interventional trial with pre-clinical and translational work including in-depth molecular profiling and biomarker discovery/development.This clinical trial is only open at the Beatson West of Scotland Cancer Centre at this time.
We carry out a wide range of basic and translational research studies to help us generally improve our understanding of how pancreatic cancer behaves and grows. Over the coming months and years, we will post more details of our projects so you can follow our activities and understand how we are working actively to fight pancreatic cancer. Our experienced team of clinicians, researchers, bioinformaticians and lab staff work tirelessly with one thing in mind: improving patient outcomes.